{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:33:48Z","timestamp":1788845628850,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007514","name":"Universit\u00e0 di Pisa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007514","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>FGF23 measurement may have a diagnostic role to investigate patients with phosphate disorders. However, normal values for infants, children, and adolescents have not been defined.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In a total of 282 (males 145, females 137) healthy infants (<jats:italic>n<\/jats:italic>\u2009=\u200930), prepubertal (<jats:italic>n<\/jats:italic>\u2009=\u2009147), pubertal (<jats:italic>n<\/jats:italic>\u2009=\u200959), and postpubertal (<jats:italic>n<\/jats:italic>\u2009=\u200946), and in twenty patients with X-linked hypophosphatemic rickets (XLH, age 10.2\u2009\u00b1\u20095.6\u00a0years) serum phosphate (automated analyzer), and plasma intact FGF23 (immunochemiluminescent sandwich assay, DiaSorin) concentrations were measured.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Intact FGF23 concentrations were higher in healthy infants than in prepubertal (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01) and postpubertal subjects (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05); pubertal subjects showed higher values (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) than postpubertal subjects. Serum phosphate concentrations were higher (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) in healthy infants than in prepubertal, pubertal, and postpubertal subjects. Pubertal subjects had higher (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) serum phosphate concentrations than postpubertal subjects. Intact FGF23 and serum phosphate concentrations did not differ (<jats:italic>P<\/jats:italic>\u2009=\u2009NS) by sex, age of menarche, and time after menarche. In healthy subjects, there was no correlation between intact FGF23 and serum phosphate concentrations. Intact FGF23 concentrations were higher (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) in patients with XLH than in healthy subjects according to chronological age and pubertal development. In all patients, intact FGF23 concentrations were above 40\u00a0pg\/mL; intact FGF23 concentrations were inversely correlated with serum phosphate concentrations (<jats:italic>r<\/jats:italic>\u2009=\u2009\u22120.65; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In healthy subjects, chronological age and puberty were main determinants of intact FGF23 concentrations. Intact FGF23 concentrations may be a useful marker for the early diagnosis of XLH in pediatric patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-023-02202-4","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T12:02:30Z","timestamp":1700654550000},"page":"873-882","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Intact FGF23 concentration in healthy infants, children, and adolescents, and diagnostic usefulness in patients with X-linked hypophosphatemic rickets"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8465-5087","authenticated-orcid":false,"given":"G. I.","family":"Baroncelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. R.","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pelosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bertelloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Michelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Toschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Piaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Peroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Comberiati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"2202_CR1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3389\/fendo.2018.00267","volume":"9","author":"RG Erben","year":"2018","unstructured":"Erben RG (2018) Physiological actions of fibroblast growth factor-23. Front Endocrinol 9:267. https:\/\/doi.org\/10.3389\/fendo.2018.00267","journal-title":"Front Endocrinol"},{"key":"2202_CR2","doi-asserted-by":"publisher","first-page":"R23","DOI":"10.1530\/JME-20-0178","volume":"66","author":"BB Ho","year":"2021","unstructured":"Ho BB, Bergwitz C (2021) FGF23 signalling and physiology. J Mol Endocrinol 66:R23\u2013R32. https:\/\/doi.org\/10.1530\/JME-20-0178","journal-title":"J Mol Endocrinol"},{"key":"2202_CR3","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1530\/JME-20-0089","volume":"66","author":"S Fukumoto","year":"2021","unstructured":"Fukumoto S (2021) FGF23-related hypophosphatemic rickets\/osteomalacia: diagnosis and new treatment. J Mol Endocrinol 66:R57\u2013R65. https:\/\/doi.org\/10.1530\/JME-20-0089","journal-title":"J Mol Endocrinol"},{"key":"2202_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00424-022-02668-w","volume":"474","author":"S Rausch","year":"2022","unstructured":"Rausch S, Foller M (2022) The regulation of FGF23 under physiological and pathophysiological conditions. Pfl\u00fcgers Archiv Eur J Physiol 474:281\u2013292. https:\/\/doi.org\/10.1007\/s00424-022-02668-w","journal-title":"Pfl\u00fcgers Archiv Eur J Physiol"},{"key":"2202_CR5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3390\/metabo12050401","volume":"12","author":"MG Vervloet","year":"2022","unstructured":"Vervloet MG (2022) Shedding light on the complex regulation of FGF23. Metabolites 12:401. https:\/\/doi.org\/10.3390\/metabo12050401","journal-title":"Metabolites"},{"key":"2202_CR6","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1681\/ASN.2005050573","volume":"16","author":"EA Imel","year":"2005","unstructured":"Imel EA, Econs MJ (2005) Fibroblast growth factor 23: roles in health and disease. J Am Soc Nephrol 16:2565\u20132575. https:\/\/doi.org\/10.1681\/ASN.2005050573","journal-title":"J Am Soc Nephrol"},{"key":"2202_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00774-011-0340-2","volume":"30","author":"TO Carpenter","year":"2012","unstructured":"Carpenter TO (2012) The expanding family of hypophosphatemic syndromes. J Bone Miner Metab 30:1\u20139. https:\/\/doi.org\/10.1007\/s00774-011-0340-2","journal-title":"J Bone Miner Metab"},{"key":"2202_CR8","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1002\/1873-3468.13494","volume":"593","author":"L Bar","year":"2019","unstructured":"Bar L, Stournaras C, Lang F, Foller M (2019) Regulation of fibroblast growth factor 23 (FGF23) in health and disease. FEBS Lett 593:1879\u20131900. https:\/\/doi.org\/10.1002\/1873-3468.13494","journal-title":"FEBS Lett"},{"key":"2202_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3389\/fendo.2020.00293","volume":"11","author":"AM Boyce","year":"2020","unstructured":"Boyce AM, Lee AE, Roszko KL, Gafni RI (2020) Hyperphosphatemic tumoral calcinosis: pathogenesis, clinical presentation, and challenges in management. Front Endocrinol 11:293. https:\/\/doi.org\/10.3389\/fendo.2020.00293","journal-title":"Front Endocrinol"},{"key":"2202_CR10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-08-0818","volume":"160","author":"SS Beck-Nielsen","year":"2009","unstructured":"Beck-Nielsen SS, Brock-Jacobsen B, Gram J, Brixen K, Jensen TK (2009) Incidence and prevalence of nutritional and hereditary rickets in Southern Denmark. Eur J Endocrinol 160:491\u2013497. https:\/\/doi.org\/10.1530\/EJE-08-0818","journal-title":"Eur J Endocrinol"},{"key":"2202_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1530\/EJE-15-0515","volume":"174","author":"S Rafaelsen","year":"2016","unstructured":"Rafaelsen S, Johansson S, Raeder H, Bjerknes R (2016) Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications. Eur J Endocrinol 174:125\u2013136. https:\/\/doi.org\/10.1530\/EJE-15-0515","journal-title":"Eur J Endocrinol"},{"key":"2202_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, Wicart P, Bockenhauer D, Santos F, Levtchenko E, Harvengt P, Kirchhoff M, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenicky P, Rejnmark L, Linglart A (2019) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 15:435\u2013455. https:\/\/doi.org\/10.1038\/s41581-019-0152-5","journal-title":"Nat Rev Nephrol"},{"key":"2202_CR13","doi-asserted-by":"publisher","first-page":"688309","DOI":"10.3389\/fendo.2021.688309","volume":"12","author":"GI Baroncelli","year":"2021","unstructured":"Baroncelli GI, Mora S (2021) X-linked hypophosphatemic rickets: multisystemic disorder in children requiring multidisciplinary management. Front Endocrinol 12:688309. https:\/\/doi.org\/10.3389\/fendo.2021.688309","journal-title":"Front Endocrinol"},{"key":"2202_CR14","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1067\/mpd.2003.119","volume":"142","author":"C Chaussain-Miller","year":"2003","unstructured":"Chaussain-Miller C, Sinding C, Wolikow M, Lasfargues JJ, Godeau G, Garabedian M (2003) Dental abnormalities in patients with familial hypophosphatemic vitamin D-resistant rickets: prevention by early treatment with 1-hydroxyvitamin D. J Pediatr 142:324\u2013331. https:\/\/doi.org\/10.1067\/mpd.2003.119","journal-title":"J Pediatr"},{"key":"2202_CR15","first-page":"61","volume":"7","author":"GI Baroncelli","year":"2006","unstructured":"Baroncelli GI, Angiolini M, Ninni E, Galli V, Saggese R, Giuca MR (2006) Prevalence and pathogenesis of dental and periodontal lesions in children with X-linked hypophosphatemic rickets. Eur J Paediatr Dent 7:61\u201366","journal-title":"Eur J Paediatr Dent"},{"key":"2202_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s00774-020-01136-8","volume":"39","author":"GI Baroncelli","year":"2021","unstructured":"Baroncelli GI, Zampollo E, Manca M, Toschi B, Bertelloni S, Michelucci A, Isola A, Bulleri A, Peroni D, Giuca MR (2021) Pulp chamber features, prevalence of abscesses, disease severity, and PHEX mutation in X-linked hypophosphatemic rickets. J Bone Miner Metab 39:212\u2013223. https:\/\/doi.org\/10.1007\/s00774-020-01136-8","journal-title":"J Bone Miner Metab"},{"key":"2202_CR17","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1258\/acb.2012.011274","volume":"49","author":"DC Fischer","year":"2012","unstructured":"Fischer DC, Mischek A, Wolf S, Rahn A, Salweski B, Kundt G, Haffner D (2012) Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase. Ann Clin Biochem 49:546\u2013553. https:\/\/doi.org\/10.1258\/acb.2012.011274","journal-title":"Ann Clin Biochem"},{"key":"2202_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bone.2014.05.012","volume":"66","author":"D Gkentzi","year":"2014","unstructured":"Gkentzi D, Efthymiadou A, Kritikou D, Chrysis D (2014) Fibroblast growth factor 23 and Klotho serum levels in healthy children. Bone 66:8\u201314. https:\/\/doi.org\/10.1016\/j.bone.2014.05.012","journal-title":"Bone"},{"key":"2202_CR19","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1210\/jc.2016-4038","volume":"102","author":"DM Mitchell","year":"2017","unstructured":"Mitchell DM, Juppner H, Burnett-Bowie SAM (2017) FGF23 is not associated with age-related changes in phosphate, but enhances renal calcium reabsorption in girls. J Clin Endocrinol Metab 102:1151\u20131160. https:\/\/doi.org\/10.1210\/jc.2016-4038","journal-title":"J Clin Endocrinol Metab"},{"key":"2202_CR20","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1515\/med-2021-0288","volume":"16","author":"M Stanczyk","year":"2021","unstructured":"Stanczyk M, Chrul S, Wyka K, Tkaczyk M (2021) Serum intact fibroblast growth factor 23 in healthy paediatric population. Open Med 16:1022\u20131027. https:\/\/doi.org\/10.1515\/med-2021-0288","journal-title":"Open Med"},{"key":"2202_CR21","doi-asserted-by":"publisher","first-page":"1018523","DOI":"10.3389\/fendo.2022.1018523","volume":"13","author":"V Brescia","year":"2022","unstructured":"Brescia V, Fontana A, Lovero R, Capobianco C, Vita Marsico S, De Chirico T, Pinto C, Varraso L, Cazzolla AP, Di Serio F (2022) Determination of iFGF23 upper reference limits (URL) in healthy pediatric population, for its better correct use. Front Endocrinol 13:1018523. https:\/\/doi.org\/10.3389\/fendo.2022.1018523","journal-title":"Front Endocrinol"},{"key":"2202_CR22","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1210\/jc.2009-1671","volume":"95","author":"EA Imel","year":"2010","unstructured":"Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ (2010) Treatment of XLH with calcitriol and phosphate increases circulating FGF23 concentrations. J Clin Endocrinol Metab 95:1846\u20131850. https:\/\/doi.org\/10.1210\/jc.2009-1671","journal-title":"J Clin Endocrinol Metab"},{"key":"2202_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/adc.73.1.17","volume":"73","author":"JV Freeman","year":"1995","unstructured":"Freeman JV, Cole TJ, Chinn S, Jones PRM, White EM, Preece MA (1995) Cross sectional stature and weight reference curves for the UK, 1990. Arch Dis Child 73:17\u201324. https:\/\/doi.org\/10.1136\/adc.73.1.17","journal-title":"Arch Dis Child"},{"key":"2202_CR24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1136\/adc.51.3.170","volume":"51","author":"JM Tanner","year":"1976","unstructured":"Tanner JM, Whitehouse RH (1976) Clinical longitudinal standards for height, weight, height velocity, weight velocity and stages of puberty. Arch Dis Child 51:170\u2013179. https:\/\/doi.org\/10.1136\/adc.51.3.170","journal-title":"Arch Dis Child"},{"key":"2202_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1297\/cpe.27.145","volume":"27","author":"T Tanaka","year":"2018","unstructured":"Tanaka T, Yokoya S, Hoshino Y, Hiro S, Ohki N (2018) Long-term safety and efficacy of daily recombinant human growth hormone treatment in Japanese short children born small for gestational age: final report from an open and multicenter study. Clin Pediatr Endocrinol 27:145\u2013157. https:\/\/doi.org\/10.1297\/cpe.27.145","journal-title":"Clin Pediatr Endocrinol"},{"key":"2202_CR26","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00223-017-0307-y","volume":"101","author":"GC Souberbielle","year":"2017","unstructured":"Souberbielle GC, Prie D, Piketty ML, Rothenbuhler A, Delanaye P, Chanson P, Cavalier E (2017) Evaluation of a new fully automated assay for plasma intact FGF23. Calcif Tissue Int 101:510\u2013518. https:\/\/doi.org\/10.1007\/s00223-017-0307-y","journal-title":"Calcif Tissue Int"},{"key":"2202_CR27","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1080\/00365513.2018.1526411","volume":"78","author":"J Van Helden","year":"2018","unstructured":"Van Helden J, Weiskirchen R (2018) Technical and diagnostic performance of a new fully automated immunoassay for the determination of intact fibroblast growth factor 23 (FGF23). Scand J Clin Lab Investig 78:584\u2013590. https:\/\/doi.org\/10.1080\/00365513.2018.1526411","journal-title":"Scand J Clin Lab Investig"},{"key":"2202_CR28","volume-title":"Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline","author":"GL Horowitz","year":"2008","unstructured":"Horowitz GL, Altaie CS, Boyd JC, Ceriotti F, Garg U, Horn P, Pesce A, Sine HE, Zakowski JCLSI (2008) Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline, 3rd edn. Clinical and Laboratory Standards Institute, Wayne","edition":"3"},{"key":"2202_CR29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000184216","volume":"44","author":"H Stark","year":"1986","unstructured":"Stark H, Eisenstein B, Tieder M, Rachmel A, Alpert G (1986) Direct measurement of TP\/GFR: a simple and reliable parameter of renal phosphate handling. Nephron 44:125\u2013128. https:\/\/doi.org\/10.1159\/000184216","journal-title":"Nephron"},{"key":"2202_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/BF00862587","volume":"2","author":"J Brodehl","year":"1988","unstructured":"Brodehl J, Krause A, Hoyer PF (1988) Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijvoet. Pediatr Nephrol 2:183\u2013189. https:\/\/doi.org\/10.1007\/BF00862587","journal-title":"Pediatr Nephrol"},{"key":"2202_CR31","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40618-022-01768-9","volume":"45","author":"M Del Pino","year":"2022","unstructured":"Del Pino M, Viterbo GL, Arenas MA, Perez Garrido N, Ramirez P, Marino R, Belgoroskly A, Fano V (2022) Growth in height and body proportion from birth to adulthood in hereditary hypophosphatemic rickets: a retrospective cohort study. J Endocrinol Invest 45:1349\u20131358. https:\/\/doi.org\/10.1007\/s40618-022-01768-9","journal-title":"J Endocrinol Invest"},{"key":"2202_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/adc.57.3.217","volume":"57","author":"K Kruse","year":"1982","unstructured":"Kruse K, Kracht U, Gopfert G (1982) Renal threshold phosphate concentration (TmPO4\/GFR). Arch Dis Child 57:217\u2013223. https:\/\/doi.org\/10.1136\/adc.57.3.217","journal-title":"Arch Dis Child"},{"key":"2202_CR33","first-page":"163","volume":"17","author":"J Brodehl","year":"1982","unstructured":"Brodehl J, Gellissen K, Weber HP (1982) Postnatal development of tubular phosphate reabsorption. Clin Nephrol 17:163\u2013171","journal-title":"Clin Nephrol"},{"key":"2202_CR34","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/clinchem\/34.8.1622","volume":"34","author":"G Lockitch","year":"1988","unstructured":"Lockitch G, Halstead AC, Albersheim S, MacCallum C, Quigley G (1988) Age- and sex-specific pediatric reference intervals for biochemistry analytes as measured with the Ektachem-700 analyzer. Clin Chem 34:1622\u20131625","journal-title":"Clin Chem"},{"key":"2202_CR35","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.bone.2008.02.014","volume":"42","author":"I Endo","year":"2008","unstructured":"Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T (2008) Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients. Proposal of diagnostic criteria using FGF23 measurement. Bone 42:1235\u20131239. https:\/\/doi.org\/10.1016\/j.bone.2008.02.014","journal-title":"Bone"},{"key":"2202_CR36","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","volume":"62","author":"I Endo","year":"2015","unstructured":"Endo I, Fukumoto S, Ozono K, Namba N, Inoue D, Okazaki R, Yamauchi M, Sugimoto T, Minagawa M, Michigami T, Nagai M, Matsumoto T (2015) Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J 62:811\u2013816. https:\/\/doi.org\/10.1507\/endocrj.EJ15-0275","journal-title":"Endocr J"},{"key":"2202_CR37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00774-011-0306-4","volume":"30","author":"Y Shimizu","year":"2012","unstructured":"Shimizu Y, Fukumoto S, Fujita T (2012) Evaluation of a new automated chemiluminescence immunoassay for FGF23. J Bone Miner Metab 30:217\u2013222. https:\/\/doi.org\/10.1007\/s00774-011-0306-4","journal-title":"J Bone Miner Metab"},{"key":"2202_CR38","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1074\/jbc.M408903200","volume":"280","author":"H Saito","year":"2005","unstructured":"Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N (2005) Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280:2543\u20132549. https:\/\/doi.org\/10.1074\/jbc.M408903200","journal-title":"J Biol Chem"},{"key":"2202_CR39","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1681\/ASN.2005111185","volume":"17","author":"S Liu","year":"2006","unstructured":"Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD (2006) Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17:1305\u20131315. https:\/\/doi.org\/10.1681\/ASN.2005111185","journal-title":"J Am Soc Nephrol"},{"key":"2202_CR40","doi-asserted-by":"publisher","first-page":"E352","DOI":"10.1210\/jc.2010-0589","volume":"95","author":"TO Carpenter","year":"2010","unstructured":"Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C, Olear E, Gundberg CM (2010) Circulating levels of soluble Klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab 95:E352\u2013E357. https:\/\/doi.org\/10.1210\/jc.2010-0589","journal-title":"J Clin Endocrinol Metab"},{"key":"2202_CR41","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Carpenter TO, Gottesman GS, Mao M, Skrinar A, San Martin J, Imel EA (2019) Efficacy and safety of burosumab in children aged 1\u20134 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol 7:189\u2013199. https:\/\/doi.org\/10.1016\/S2213-8587(18)30338-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2202_CR42","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, H\u00f6gler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen CY, Skrinar A, San Martin J, Portale AA (2019) Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 393:2416\u20132427. https:\/\/doi.org\/10.1016\/S0140-6736(19)30654-3","journal-title":"Lancet"},{"key":"2202_CR43","doi-asserted-by":"publisher","first-page":"e3241","DOI":"10.1210\/clinem\/dgac296","volume":"107","author":"LM Ward","year":"2022","unstructured":"Ward LM, Glorieux FH, Whyte MP, Munns CF, Portale AA, H\u00f6gler W, Simmons JH, Gottesman GS, Padidela R, Namba N, Cheong HI, Nilsson O, Mao M, Chen A, Skrinar A, Roberts MS, Imel EA (2022) Effect of burosumab compared with conventional therapy on younger vs older children with X-linked hypophosphatemia. J Clin Endocrinol Metab 107:e3241\u2013e3253. https:\/\/doi.org\/10.1210\/clinem\/dgac296","journal-title":"J Clin Endocrinol Metab"},{"key":"2202_CR44","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1172\/JCI32409","volume":"117","author":"IZ Ben-Dov","year":"2007","unstructured":"Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J (2007) The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003\u20134008. https:\/\/doi.org\/10.1172\/JCI32409","journal-title":"J Clin Invest"},{"key":"2202_CR45","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1677\/JOE-07-0267","volume":"195","author":"T Krajisnik","year":"2007","unstructured":"Krajisnik T, Bj\u00f6rklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson KB, Westin G, Larsson TE (2007) Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195:125\u2013131. https:\/\/doi.org\/10.1677\/JOE-07-0267","journal-title":"J Endocrinol"},{"key":"2202_CR46","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00223-017-0333-9","volume":"102","author":"ML Mace","year":"2018","unstructured":"Mace ML, Gravesen E, Nordholm A, Olgaard K, Lewin E (2018) Fibroblast growth factor (FGF) 23 regulates the plasma levels of parathyroid hormone in vivo through the FGF receptor in normocalcemia, but not in hypocalcemia. Calcif Tissue Int 102:85\u201392. https:\/\/doi.org\/10.1007\/s00223-017-0333-9","journal-title":"Calcif Tissue Int"},{"key":"2202_CR47","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1093\/clinchem\/37.11.1999","volume":"37","author":"G Saggese","year":"1991","unstructured":"Saggese G, Baroncelli GI, Bertelloni S (1991) Determination of intact parathyrin by immunoradiometric assay evaluated in normal children and in patients with various disorders of calcium metabolism. Clin Chem 37:1999\u20132001","journal-title":"Clin Chem"},{"key":"2202_CR48","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/j.1365-2265.2003.01685.x","volume":"58","author":"O Makitie","year":"2003","unstructured":"Makitie O, Kooh SW, Sochett E (2003) Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets. Clin Endocrinol 58:163\u2013168. https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01685.x","journal-title":"Clin Endocrinol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02202-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02202-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02202-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T01:23:48Z","timestamp":1711502628000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02202-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["2202"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02202-4","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]},"assertion":[{"value":"15 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the ethics committee for human investigation of the Department of Obstetrics, Gynecology and Pediatrics of the University Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study was conducted according to the Declaration of Helsinki II and the Good Clinical Practice guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"All parents of both patients and healthy subjects provided informed consent to participate in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}